RxDoctor Payments Data

Kathleen Watson, MD

Family Medicine · Conroe, TXNPI 1528295094

Payments from drug & device makers

$1,471in general payments, 2019–2025

Across 96 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$293
  • Novo Nordisk$243
  • Pfizer$164
  • AbbVie$136
  • Lilly USA, LLC$113
  • Amgen$85
  • plus $436 from 14 others

What the payments were for

  • Food & beverage$1,465100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,471 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$73,456
Medicare patients
200
Services billed
1,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$52,200
OzempicSemaglutide20$45,878
EliquisApixaban32$28,164
JanuviaSitagliptin Phosphate18$22,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$20,683
TradjentaLinagliptin12$17,678
RybelsusSemaglutide14$15,811
XareltoRivaroxaban12$10,522
MyrbetriqMirabegron12$10,196
Breo ElliptaFluticasone/Vilanterol15$7,914
SymbicortBudesonide/Formoterol Fumarate15$7,827
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,657
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,125
Levothyroxine Sodium267$2,999
Duloxetine Hcl81$2,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$243$61,68934 claims
GSKTrelegy Ellipta, Breo Ellipta$18$28,59637 claims
PfizerEliquis$164$28,16432 claims
Johnson & JohnsonXarelto$67$10,52212 claims
Astellas Pharma US IncMyrbetriq$49$10,19612 claims
AstraZenecaSymbicort$293$7,82715 claims
AbbVieSynthroid$136$83938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →